title: [Update on Current Care Guideline: Multiple sclerosis].
abstract: Treatment for relapsing-remitting multiple sclerosis (RRMS) is initiated upon fulfillment of new McDonald 2010 criteria for RRMS. In addition, lumbar puncture is an essential diagnostic method. Interferon-β, dimethyl fumarate, glatiramer acetate and teriflunomide are the first-line immunomodulating drugs (IMD) for RRMS. If the disease is active according to clinical or MRI evaluation during the first-line IMD treatment, alemtuzumab, fingolimod or natalizumab may be considered as second-line therapies. IMD treatment is discontinued upon the transition of RRMS to secondary progressive phase. Rehabilitation should be considered at every phase of the disease.
authors.forename: Anne
authors.initials: A
authors.lastname: Remes
authors.forename: Laura
authors.initials: L
authors.lastname: Airas
authors.forename: Sari
authors.initials: S
authors.lastname: Atula
authors.forename: Markus
authors.initials: M
authors.lastname: Färkkilä
authors.forename: Päivi
authors.initials: P
authors.lastname: Hartikainen
authors.forename: Keijo
authors.initials: K
authors.lastname: Koivisto
authors.forename: Eliisa
authors.initials: E
authors.lastname: Mäenpää
authors.forename: Juhani
authors.initials: J
authors.lastname: Ruutiainen
authors.forename: Marja-Liisa
authors.initials: ML
authors.lastname: Sumelahti
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000175:diagnosis* / Q000188:drug therapy*; D013129:Spinal Puncture
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D007166:Immunosuppressive Agents